Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. (28th July 2021)
- Record Type:
- Journal Article
- Title:
- Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. (28th July 2021)
- Main Title:
- Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity
- Authors:
- Metheny, Leland
Eid, Saada
Wuttisarnwattana, Patiwet
Auletta, Jeffery J.
Liu, Chen
Van Dervort, Alana
Paez, Conner
Lee, ZhengHong
Wilson, David
Lazarus, Hillard M.
Deans, Robert
Vant Hof, Wouter
Ktena, Yiouli
Cooke, Kenneth R. - Abstract:
- Abstract: Graft-vs-host disease (GvHD) limits successful outcomes following allogeneic blood and marrow transplantation (allo-BMT). We examined whether the administration of human, bone marrow-derived, multipotent adult progenitor cells (MAPCs™) could regulate experimental GvHD. The immunoregulatory capacity of MAPC cells was evaluated in vivo using established murine GvHD models. Injection of MAPC cells on day +1 (D1) and +4 (D4) significantly reduced T-cell expansion and the numbers of donor-derived, Tumor Necrosis Factor Alpha (TNFα) and Interferon Gamma (IFNγ)-producing, CD4+ and CD8+ cells by D10 compared with untreated controls. These findings were associated with reductions in serum levels of TNFα and IFNγ, intestinal and hepatic inflammation and systemic GvHD as measured by survival and clinical score. Biodistribution studies showed that MAPC cells tracked from the lung and to the liver, spleen, and mesenteric nodes within 24 hours after injection. MAPC cells inhibited mouse T-cell proliferation in vitro and this effect was associated with reduced T-cell activation and inflammatory cytokine secretion and robust increases in the concentrations of Prostaglandin E2 (PGE2) and Transforming Growth Factor Beta (TGFβ). Indomethacin and E-prostanoid 2 (EP2) receptor antagonism both reversed while EP2 agonism restored MAPC cell-mediated in vitro T-cell suppression, confirming the role for PGE2. Furthermore, cyclo-oxygenase inhibition following allo-BMT abrogated theAbstract: Graft-vs-host disease (GvHD) limits successful outcomes following allogeneic blood and marrow transplantation (allo-BMT). We examined whether the administration of human, bone marrow-derived, multipotent adult progenitor cells (MAPCs™) could regulate experimental GvHD. The immunoregulatory capacity of MAPC cells was evaluated in vivo using established murine GvHD models. Injection of MAPC cells on day +1 (D1) and +4 (D4) significantly reduced T-cell expansion and the numbers of donor-derived, Tumor Necrosis Factor Alpha (TNFα) and Interferon Gamma (IFNγ)-producing, CD4+ and CD8+ cells by D10 compared with untreated controls. These findings were associated with reductions in serum levels of TNFα and IFNγ, intestinal and hepatic inflammation and systemic GvHD as measured by survival and clinical score. Biodistribution studies showed that MAPC cells tracked from the lung and to the liver, spleen, and mesenteric nodes within 24 hours after injection. MAPC cells inhibited mouse T-cell proliferation in vitro and this effect was associated with reduced T-cell activation and inflammatory cytokine secretion and robust increases in the concentrations of Prostaglandin E2 (PGE2) and Transforming Growth Factor Beta (TGFβ). Indomethacin and E-prostanoid 2 (EP2) receptor antagonism both reversed while EP2 agonism restored MAPC cell-mediated in vitro T-cell suppression, confirming the role for PGE2. Furthermore, cyclo-oxygenase inhibition following allo-BMT abrogated the protective effects of MAPC cells. Importantly, MAPC cells had no effect on the generation cytotoxic T lymphocyte activity in vitro, and the administration of MAPC cells in the setting of leukemic challenge resulted in superior leukemia-free survival. Collectively, these data provide valuable information regarding the biodistribution and regulatory capacity of MAPC cells, which may inform future clinical trial design. Abstract : Bio-redistribution of multipotent adult progenitor cells from the lung and to the liver and spleen of allogeneic blood and marrow transplantation recipient mice as captured by 3D, computer-generated imagery. … (more)
- Is Part Of:
- Stem cells. Volume 39:Number 11(2021)
- Journal:
- Stem cells
- Issue:
- Volume 39:Number 11(2021)
- Issue Display:
- Volume 39, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 39
- Issue:
- 11
- Issue Sort Value:
- 2021-0039-0011-0000
- Page Start:
- 1506
- Page End:
- 1519
- Publication Date:
- 2021-07-28
- Subjects:
- Immune modulation -- inflammation -- lymphocytes -- prostaglandin
Cloning -- Periodicals
Clone cells -- Periodicals
Stem cells -- Periodicals
Cell Differentiation -- Periodicals
Cell Division -- Periodicals
Clone Cells -- Periodicals
Hematopoietic Stem Cells -- Periodicals
Stem Cells -- Periodicals
571.84 - Journal URLs:
- https://academic.oup.com/stmcls ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/stem.3434 ↗
- Languages:
- English
- ISSNs:
- 1066-5099
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8464.133510
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20731.xml